Wheat oligopeptide as well as preparation method and application thereof

By preparing wheat oligopeptides with specific ratios of Ala-Leu, Ala-IIe, and IIe-Met peptides, the problem of insufficient research on the proliferation and apoptosis of wheat oligopeptides in myoblast C2C12 cells in existing technologies has been solved, achieving significant inhibition of apoptosis and promotion of proliferation, thus expanding the scope of applications.

CN119019487APending Publication Date: 2024-11-26CHINA NAT RES INST OF FOOD & FERMENTATION IND CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411205135.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-29
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

There is limited research on the effects of wheat oligopeptides on the proliferation and apoptosis of myoblast C2C12 cells in existing technologies, which restricts their development and application.

Method used

By using wheat oligopeptides with specific ratios of Ala-Leu, Ala-IIe, and IIe-Met peptides, combined with trypsin and neutral protease hydrolysis, centrifugation-preliminary separation, filtration, and resin purification processes, a product was prepared that significantly inhibits C2C12 apoptosis of myoblasts or promotes their proliferation.

Benefits of technology

It significantly inhibits C2C12 apoptosis of myoblasts or promotes their proliferation, expanding the development direction of wheat oligopeptides and providing new raw materials for the treatment of sarcopenia.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119019487A_ABST
    Figure CN119019487A_ABST
Patent Text Reader

Abstract

The invention provides wheat oligopeptide as well as a preparation method and application thereof. The wheat oligopeptide at least comprises peptide fragments of Ala-Leu, Ala-IIe and IIe-Met, wherein the mass content of the Ala-Leu ranges from 0.2% to 0.4%, the mass content of the Ala-IIe ranges from 0.5% to 0.7%, and the mass content of the IIe-Met ranges from 0.02% to 0.05%. The wheat oligopeptide can effectively promote muscle regeneration and reduce myoblast C2C12 apoptosis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a wheat oligopeptide, in particular to a wheat oligopeptide and a preparation method and application thereof, belonging to the technical field of wheat oligopeptide production. Background Art

[0002] Wheat oligopeptides refer to a class of low molecular weight polypeptide compounds present in wheat. These polypeptide compounds are decomposed from the protein in wheat and usually contain 2 to 10 amino acid residues. They can be formed during the digestion process or during wheat processing.

[0003] Specifically, wheat oligopeptides are generally made from wheat gluten (wheat protein isolate powder) as raw materials, and are prepared through processes such as slurry adjustment, enzymolysis, separation, purification, and drying. In the current production process, more attention is paid to the oligopeptide content in wheat oligopeptides, and as many dipeptides and tripeptides as possible are retained. For example, patent CN104593319A records a preparation process for wheat oligopeptides, in which wheat gluten is enzymolyzed with non-specific proteases and specific proteases in turn, and the resulting enzymolysis solution is successively centrifuged, microfiltered, cation exchanged, nanofiltered, and ultrafiltered to obtain wheat oligopeptide products.

[0004] However, there are few studies on the effects of wheat oligopeptides on the proliferation and apoptosis of myoblasts C2C12, which limits the development and use of wheat oligopeptides. Summary of the invention

[0005] The invention provides a wheat oligopeptide, which has a peptide segment with a specific mass percentage and can significantly inhibit the apoptosis of myoblasts C2C12 or promote the proliferation of myoblasts C2C12.

[0006] The present invention also provides a method for preparing the wheat oligopeptide, which can prepare the wheat oligopeptide.

[0007] The present invention also provides an application of the wheat oligopeptide in a product for inhibiting apoptosis of myoblast C2C12 and promoting proliferation of myoblast C2C12. The product can significantly inhibit apoptosis of myoblast C2C12 or promote proliferation of myoblast C2C12.

[0008] The present invention provides a wheat oligopeptide, wherein the wheat oligopeptide comprises at least peptide segments Ala-Leu, Ala-IIe and IIe-Met;

[0009] The mass content of Ala-Leu is 0.2%-0.4%, the mass content of Ala-IIe is 0.5%-0.7%, and the mass content of IIe-Met is 0.02%-0.05%.

[0010] In the wheat oligopeptide as described above, the mass content of Ala-Leu is 0.2%-0.3%, the mass content of Ala-IIe is 0.6%-0.7%, and the mass content of IIe-Met is 0.02%-0.04%.

[0011] The wheat oligopeptide as described above has a protein content of 95%-99%, a free amino acid content of 2%-5%, and a component content of less than 1000Da relative molecular weight of 92%-94%.

[0012] In another aspect, the present invention provides a method for preparing the wheat oligopeptide as described above, comprising the following steps:

[0013] 1) using trypsin and neutral protease to enzymatically hydrolyze the gluten solution in sequence to obtain a first enzymatic hydrolyzate;

[0014] 2) performing centrifugation and preliminary separation treatment on the first enzymatic hydrolysate in sequence to obtain a second enzymatic hydrolysate with a molecular weight of 200-1000 Da;

[0015] 3) The second enzymatic hydrolysate is sequentially subjected to filtration treatment, macroporous adsorption resin purification treatment, and cation exchange resin purification treatment to obtain wheat oligopeptides.

[0016] In the preparation method as described above, in step 1), the mass ratio of gluten to water in the gluten solution is 1:(10-20);

[0017] The trypsin added to every 100g of the gluten powder is 2000U;

[0018] The neutral protease added to each 100g of the gluten powder is 0.8Au.

[0019] In the preparation method as described above, in step 2), the centrifugation-preliminary separation process comprises the following steps:

[0020] The first enzymatic hydrolysate is centrifuged to separate the supernatant, and then the supernatant is separated using a 1000Da membrane to obtain a filtrate including the target product;

[0021] The filtrate is separated using a 200Da membrane to obtain the second enzymatic hydrolyzate with a molecular weight of 200-1000Da.

[0022] In the preparation method as described above, the rotation speed in the centrifugal filtration treatment is 200-400 rpm / min, and the pore size of the filter membrane is 120-160 nm.

[0023] The preparation method as described above, wherein the macroporous adsorption resin purification process comprises the following steps:

[0024] The enzymatic hydrolysate after centrifugal filtration is passed through a macroporous adsorption resin column at a linear flow rate of 1-5 mL / min, and the effluent is collected when the ultraviolet detection value reaches 50 mAu, and the effluent is stopped when the ultraviolet detection value is lower than 100 mAu;

[0025] And / or, the cation exchange resin purification process comprises the following steps:

[0026] The enzymatic hydrolyzate separated and purified by the macroporous adsorption resin is passed through a cation exchange resin column at a linear flow rate of 1-10 mL / min, and the effluent is collected when the ultraviolet detection value reaches 100 mAu, and the effluent is stopped when the ultraviolet detection value is lower than 200 mAu.

[0027] The preparation method as described above further comprises spray drying the wheat oligopeptide, wherein the inlet temperature of the spray drying is 160-170°C and the outlet temperature is 60-80°C.

[0028] In another aspect, the present invention provides a use of the wheat oligopeptide as described above in a product for inhibiting apoptosis of myoblasts C2C12 and / or promoting proliferation of myoblasts C2C12.

[0029] The wheat oligopeptide provided by the present invention has Ala-Leu peptide segment, Ala-IIe peptide segment and IIe-Met peptide segment with specific mass percentage, and under the synergistic effect of each peptide segment, can inhibit the apoptosis of myoblast C2C12 or promote the proliferation of myoblast C2C12, thus expanding the development direction of wheat oligopeptide. BRIEF DESCRIPTION OF THE DRAWINGS

[0030] Figure 1 A liquid chromatogram obtained by size exclusion chromatography separation of the wheat oligopeptide provided in Example 1 of the present invention;

[0031] Figure 2A The mass spectrum of AI product ions in wheat oligopeptides provided in Example 1 of the present invention;

[0032] Figure 2B The mass spectrum of IM product ions in wheat oligopeptides provided in Example 1 of the present invention;

[0033] Figure 2C The mass spectrum of AL product ions in wheat oligopeptides provided in Example 1 of the present invention;

[0034] Figure 3A This is the quantitative chromatogram of peptide AL standard;

[0035] Figure 3B The quantitative chromatogram of wheat oligopeptide peptide segment AL provided in Example 1 of the present invention;

[0036] Figure 3C The wheat oligopeptide peptide segment AL calibration curve provided in Example 1 of the present invention;

[0037] Figure 4A This is the quantitative chromatogram of the peptide AI standard;

[0038] Figure 4B The quantitative chromatogram of wheat oligopeptide peptide AI provided in Example 1 of the present invention;

[0039] Figure 4C The AI ​​calibration curve of wheat oligopeptide peptides provided in Example 1 of the present invention;

[0040] Figure 5A The quantitative chromatogram of the peptide IM standard;

[0041] Figure 5B The quantitative chromatogram of wheat oligopeptide peptide segment IM provided in Example 1 of the present invention;

[0042] Figure 5C The wheat oligopeptide peptide segment IM calibration curve provided in Example 1 of the present invention;

[0043] Fig. 6A A bar graph showing that wheat oligopeptides provided in Example 1 of the present invention promote proliferation of myoblast C2C12 cells;

[0044] Figure 6B A bar graph showing that wheat oligopeptides provided in Example 1 of the present invention inhibit apoptosis of myoblast C2C12 cells;

[0045] Fig. 7A PCA based on the FPKM values ​​of all genes measured after C2C12 cells were treated with the wheat oligopeptide provided in Example 1 of the present invention;

[0046] Figure 7B After the wheat oligopeptide provided in Example 1 of the present invention was used to treat C2C12 cells, all differentially expressed genes (DEGS) between the treated and control samples were displayed based on DEseq2, P < 0.05 and FC ≥ 1.5 or ≤ 0.67;

[0047] Figure 7C The FPKM hierarchical clustering heat map of all DEGs after C2C12 cells were treated with wheat oligopeptides provided in Example 1 of the present invention;

[0048] Fig.7D The most enriched GO analysis results of upregulated DEGs after C2C12 cells were treated with wheat oligopeptides provided in Example 1 of the present invention;

[0049] Fig. 7EThe most enriched GO analysis results of down-regulated DEGs after C2C12 cells were treated with wheat oligopeptides provided in Example 1 of the present invention;

[0050] Fig. 8A A pathway diagram showing the top 10 up-regulated genes enriched after C2C12 cells were treated with wheat oligopeptides provided in Example 1 of the present invention;

[0051] Figure 8B A pathway diagram showing the top 10 genes enriched in down-regulated expression after C2C12 cells were treated with wheat oligopeptides provided in Example 1 of the present invention;

[0052] Fig. 9 The first 10 key gene maps of wheat oligopeptide differentially expressed mRNA provided in Example 1 of the present invention;

[0053] Fig. 10A This is an annotation diagram of the wheat oligopeptide provided in Example 1 of the present invention;

[0054] Fig. 10B The FPKM and statistical difference diagram of the important Hub genes of wheat oligopeptides provided in Example 1 of the present invention;

[0055] Fig.11 This is a graph showing the qPCR results of wheat oligopeptides provided in Example 1 of the present invention. DETAILED DESCRIPTION

[0056] In order to make the purpose, technical solutions and advantages of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below in combination with the embodiments of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0057] On one hand, the present invention provides a wheat oligopeptide, which comprises at least peptide segments Ala-Leu, Ala-IIe and IIe-Met; wherein the mass content of Ala-Leu is 0.2%-0.4%, the mass content of Ala-IIe is 0.5%-0.7%, and the mass content of IIe-Met is 0.02%-0.05%.

[0058] In detail, the wheat oligopeptide provided by the present invention is prepared by subjecting gluten powder to protease hydrolysis and then undergoing multi-step separation and purification.

[0059] Among them, Ala-Leu (AL) is a peptide composed of alanine (Ala) and leucine (Leu). The chemical structure of this peptide is -Ala-Leu-, where -Ala- represents an alanine residue and -Leu- represents a leucine residue.

[0060] Ala-Ile (AI) is a peptide composed of alanine (Ala) and isoleucine (Ile). The chemical structure of this peptide is -Ala-Ile-, where -Ala- represents an alanine residue and -Ile- represents an isoleucine residue.

[0061] IIe-Met (IM) refers to a peptide composed of isoleucine (Ile) and methionine (Met). The chemical structure of this peptide is -IIe-Met-, where -IIe- represents an isoleucine residue and -Met- represents a methionine residue.

[0062] The mass content of Ala-Leu, the mass content of Ala-IIe and the mass content of IIe-Met in the present invention are all based on the dry mass content of wheat oligopeptides.

[0063] Chromatographic separation, mass spectrometry scanning, PIS scanning and other methods can be used to perform peptide analysis on wheat oligopeptides.

[0064] The wheat oligopeptide provided by the present invention can promote the proliferation of myoblast C2C12 and inhibit the apoptosis of myoblast C2C12. In the experiment of the wheat oligopeptide provided by the present invention on myoblast C2C12, 370 differential genes were identified, 109 genes were upregulated, 261 genes were downregulated, and FC≥3 / 2or≤2 / 3. After analysis, the upregulated gene expression was mainly enriched in related pathways such as inflammatory response, immune response, TNF signaling pathway and IL-17 signaling pathway, and the downregulated gene expression was mainly enriched in related pathways such as oxidation-reduction process, and the PPI interaction parameter interaction score≥0.7. The top 10 hub genes were obtained from the differential genes of PPI, and chemokines CXCL1, CCL5, CCL2, CXCL5, CXCR4, Il6 and MMP3 were screened. After analysis, hub genes tend to be enriched in chemokine-mediated signaling pathways, cell responses to chemokines, and chemokine responses as biological processes, among which chemokine CXCL1, CCL2, and CCL5 genes are related to C2C12. Therefore, it can be revealed that the wheat oligopeptides provided by the present invention can promote C2C12 proliferation and inhibit cell apoptosis. In addition, wheat oligopeptides inhibit apoptosis of myoblasts by regulating the expression of chemokines such as CXCL1, CCL5, CCL2, CXCL5, and CXCR4.

[0065] Furthermore, in a specific embodiment of the present invention, the mass content of Ala-Leu is 0.2%-0.3%, the mass content of Ala-IIe is 0.6%-0.7%, and the mass content of IIe-Met is 0.02%-0.04%.

[0066] When the peptide segment of wheat oligopeptide is within the above range, it can better inhibit the apoptosis of myoblasts C2C12.

[0067] Furthermore, in a specific embodiment of the present invention, the protein content of the wheat oligopeptide is 95%-99%, the free amino acid content is 2%-5%, and the content of components with a relative molecular weight of less than 1000 Da is 92%-94%.

[0068] Among them, the protein content, free amino acid content and the content of other components in wheat oligopeptides can be detected by common detection methods in the art.

[0069] The protein content, free amino acid content and content of components with a relative molecular weight of 1000 Da or less in the present invention refer to dry basis content.

[0070] For example, the protein content in wheat oligopeptides can be detected by the Kjeldahl method or the Bradford method; the free amino acid content can be determined by amino acid analysis, mass spectrometry, enzymatic hydrolysis, etc.

[0071] In another aspect, the present invention provides a method for preparing the wheat oligopeptide as described above, comprising the following steps:

[0072] 1) using trypsin and neutral protease to enzymatically hydrolyze the gluten solution in sequence to obtain a first enzymatic hydrolyzate;

[0073] 2) performing centrifugation-preliminary separation treatment on the first enzymatic hydrolysate in sequence to obtain a second enzymatic hydrolysate with a molecular weight of 200-1000Da;

[0074] 3) The second enzymatic hydrolysate is sequentially subjected to filtration treatment, macroporous adsorption resin purification treatment, and cation exchange resin purification treatment to obtain wheat oligopeptides.

[0075] The inventor has conducted a lot of research and exploration on how to make the enzymatic hydrolyzate of gluten powder contain the expected mass content of peptide segments Ala-Leu, Ala-IIe and IIe-Met, and proved that the selection of enzyme preparations, the process of enzyme treatment and the corresponding separation and purification process have a key influence on the results. The inventor unexpectedly found in the research process that only by using trypsin and neutral protease to perform successive enzymatic hydrolysis respectively, and centrifuging-preliminary separation treatment, filtering treatment and purification treatment on the enzymatic hydrolyzate, can it be helpful to obtain wheat oligopeptides including 0.2%-0.4% Ala-Leu peptide content, 0.5%-0.7% Ala-IIe peptide content, and 0.02%-0.05% IIe-Met peptide.

[0076] Specifically, the gluten solution used in the present invention refers to a mixture of gluten and water. The gluten solution has a certain fluidity and a larger surface area than gluten, which is conducive to subsequent enzymatic hydrolysis.

[0077] The present invention does not limit the specific type and source of gluten. To ensure the efficiency of enzymatic treatment, the present invention can select gluten with a protein content greater than 80%, such as gluten with a protein content of 80%-85%.

[0078] It is understood that in order to improve the uniformity of the gluten solution, the gluten and water may be mixed and stirred at a certain speed.

[0079] In step 1), firstly, trypsin is added to the gluten solution to perform enzymatic hydrolysis on the gluten solution, and then neutral protease is added to continue the enzymatic hydrolysis. Then, the enzyme is inactivated and the supernatant is taken after centrifugation to obtain the first enzymatic hydrolyzate.

[0080] When the gluten solution is enzymatically treated with trypsin, the protein in the gluten can be decomposed into small molecular peptide chains and amino acids. Subsequently, the peptide chains in the gluten solution are further decomposed into shorter peptide segments and amino acids under the action of neutral protease to obtain the first enzymatic hydrolyzate.

[0081] In order to better exert the enzymatic hydrolysis effect of trypsin and neutral protease, it is necessary to control the enzymatic hydrolysis treatment under appropriate conditions, wherein the enzymatic hydrolysis temperature of trypsin is 35-40°C, the time is 30-60min, and the pH is 7.5-8.5; the enzymatic hydrolysis temperature of neutral protease is 35-45°C, the time is 10-30min, and the pH is 6.5-7.5. The pH of the enzymatic hydrolysis treatment can be adjusted using sodium hydroxide NaOH or hydrochloric acid HCl.

[0082] The enzyme inactivation treatment may be carried out by conventional enzyme inactivation methods in the art, for example, enzyme inactivation treatment at 95° C. for 15 minutes.

[0083] In step 2), the first enzymatic hydrolysate is subjected to centrifugation-preliminary separation treatment to obtain a second enzymatic hydrolysate with a molecular weight of 200-1000Da.

[0084] The present invention does not limit the specific operation of the centrifugation-primary separation treatment, as long as the second enzymatic hydrolyzate with a molecular weight of 200-1000Da can be obtained.

[0085] For example, the first enzymatic hydrolysate can be treated by ultrafiltration / dialysis, centrifugal concentration, gel filtration chromatography, etc., to obtain a second enzymatic hydrolysate with a molecular weight of 200-1000 Da.

[0086] By subjecting the first enzymatic hydrolysate to a centrifugal and preliminary separation treatment, small molecule peptide chains and amino acids can be initially concentrated, making them suitable for further purification treatment.

[0087] In step 3), the second enzymatic hydrolyzate is sequentially subjected to filtration treatment, macroporous adsorption resin purification treatment, and cation exchange resin purification treatment to obtain wheat oligopeptides.

[0088] The second enzymatic hydrolysate is filtered to remove residual macromolecular substances and solid particles to make the solution clearer and more concentrated.

[0089] The macroporous adsorption resin in the present invention is a type of polymer adsorption resin that does not contain exchange groups and has a macroporous structure. It has a good macroporous network structure and a large specific surface area, and can selectively physically adsorb non-polar amino acids and other substances in the enzymatic hydrolyzate. The macroporous adsorption resin is generally white spherical particles with a particle size of 20-60 meshes. In the specific implementation process of the present invention, in order to effectively physically adsorb non-polar amino acids and other substances in the enzymatic hydrolyzate, a non-polar macroporous adsorption resin is used.

[0090] In order to further improve the separation and purification effect, the macroporous adsorption resin column was rinsed with deionized water after the sample was loaded.

[0091] The enzymatic hydrolyzate after separation and purification by macroporous adsorption resin is passed through a cation exchange resin column at a linear flow rate of 5 mL / min. When the ultraviolet detection value reaches 100 mAu, the effluent is collected, and when the ultraviolet detection value is lower than 200 mAu, the effluent is stopped. Specifically, the cation exchange resin column used is a pre-balanced hydrogen-type cation exchange resin column, and the cation exchange resin used is a food-grade cation exchange resin, specifically an acrylic resin, and its particle size is 0.5-1.0 mm. In order to further improve the separation and purification effect, after the sample is loaded, the cation exchange resin is continuously rinsed with deionized water.

[0092] Through the above process, not only can the peptide segments Ala-Leu, Ala-IIe and IIe-Met be obtained, but also the mass content of the peptide segment Ala-Leu can be 0.28%, the mass content of Ala-IIe can be 0.64%, and the mass content of IIe-Met can be 0.03%.

[0093] Furthermore, in a specific embodiment of the present invention, in step 1), the mass ratio of gluten to water in the gluten solution is 1:(10-20); 2000U of trypsin is added per 100g of gluten; and 0.8Au of neutral protease is added per 100g of gluten.

[0094] Among them, when the mass ratio of gluten to water in the gluten solution is 1: (10-20), it can avoid adding too little water, resulting in poor fluidity, which is not conducive to the action of the enzyme preparation and easily leads to reduced enzymatic hydrolysis efficiency; it can also avoid adding too much water, resulting in an excessively large reaction volume during enzymatic hydrolysis, which increases the load of subsequent treatments (such as separation and purification treatments, etc.) and the treatment cost will also increase accordingly.

[0095] The inventors found that when 2000U of trypsin was added to every 100g of gluten powder and 0.8Au of neutral protease was added to every 100g of gluten powder, it was beneficial to further exert the effect of the enzyme preparation and increase the mass content of functional peptides in wheat oligopeptides.

[0096] Further, in a specific embodiment of the present invention, in step 2), the centrifugation-preliminary separation treatment includes the following steps: centrifuging the first enzymatic hydrolysate to separate the supernatant, and then separating the supernatant using a 1000Da membrane to obtain a filtrate including the target product; separating the filtrate using a 200Da membrane to obtain a second enzymatic hydrolysate with a molecular weight of 200-1000Da.

[0097] The centrifugation-primary separation treatment of the first enzymatic hydrolysate using a 1000Da membrane and a 200Da membrane can not only achieve precise separation, but also is simple to operate and can more effectively retain the biological activity and functionality of the target product.

[0098] Furthermore, in a specific embodiment of the present invention, the rotation speed in the centrifugal filtration treatment is 200-400 rpm / min, and the pore size of the filter membrane is 120-160 nm.

[0099] When the above filter membrane and rotation speed are used for centrifugal filtration, the precipitate in the enzymolysis solution can be removed, the enzymolysis solution can be clarified, and the impurities in the enzymolysis solution can be removed.

[0100] Further, in a specific embodiment of the present invention, the macroporous adsorption resin purification treatment comprises the following steps: passing the enzymatic hydrolysate after centrifugal filtration through a macroporous adsorption resin column at a linear flow rate of 1-5 mL / min, starting to collect the effluent when the ultraviolet detection value reaches 50 mAu, and stopping to collect the effluent when the ultraviolet detection value is lower than 100 mAu; and / or, the cation exchange resin purification treatment comprises the following steps: passing the enzymatic hydrolysate after separation and purification treatment with a macroporous adsorption resin through a cation exchange resin column at a linear flow rate of 1-10 mL / min, starting to collect the effluent when the ultraviolet detection value reaches 100 mAu, and stopping to collect the effluent when the ultraviolet detection value is lower than 200 mAu.

[0101] After the above separation and purification treatment, the target product can be obtained efficiently.

[0102] Furthermore, in a specific embodiment of the present invention, the wheat oligopeptide is spray-dried, and the inlet temperature of the spray-drying treatment is 160-170°C, and the outlet temperature is 60-80°C.

[0103] After spray drying, powdered wheat oligopeptide, namely wheat oligopeptide powder, can be obtained, which is more convenient for the application of wheat oligopeptide.

[0104] In another aspect, the present invention provides a use of the wheat oligopeptide as described above in a product for inhibiting apoptosis of myoblasts C2C12 and / or promoting proliferation of myoblasts C2C12.

[0105] It is understood that the products include but are not limited to food, health products and medicines. A large amount of research data proves that the wheat oligopeptides of the present invention, including 0.2%-0.4% Ala-Leu peptide content, 0.5%-0.7% Ala-IIe peptide content, and 0.02%-0.05% IIe-Met peptide content, have the ability to significantly inhibit the apoptosis of myoblasts C2C12, and can be applied not only to food and health products in the conventional sense, but also to the preparation of anti-sarcopenia drugs, etc., thereby broadening the application range of wheat oligopeptides and providing new raw materials for the treatment of sarcopenia.

[0106] Among them, the mass proportion of wheat oligopeptides in the product can be adjusted according to factors such as the target object, target effect, and product type to achieve targeted use of wheat oligopeptides.

[0107] The technical solution of the present application will be further explained below in conjunction with specific examples. The experimental methods in the following examples that do not specify specific conditions are usually carried out under conventional conditions or under conditions recommended by the manufacturer. The reagents used are commercially available or available from public channels unless otherwise specified.

[0108] Example 1

[0109] 1. Preparation of wheat oligopeptides

[0110] 1) After gluten powder is mixed with water, trypsin and neutral protease are added in sequence for enzymolysis, and the enzymes are inactivated to obtain a first enzymolysis solution, wherein: the mass ratio of gluten powder to water is 1:15; and the trypsin and neutral protease added per 100g gluten powder are 2000U and 0.8Au, respectively.

[0111] 2) The supernatant obtained in the above enzymatic hydrolysis step is subjected to centrifugation-preliminary separation treatment by membrane interception: the first enzymatic hydrolyzate is centrifuged to separate the supernatant, and then the supernatant is first separated by a 1000Da membrane to obtain a filtrate, and then separated by a 200Da membrane to obtain a retentate to obtain a second enzymatic hydrolyzate with a molecular weight between 200Da and 1000Da.

[0112] 3) The second enzymatic hydrolyzate is sequentially subjected to filtration treatment, macroporous adsorption resin purification treatment, and cation exchange resin purification treatment:

[0113] Among them, a filter membrane with a pore size of 150nm is used for filtration treatment, and then the enzymatic hydrolysate after centrifugal filtration is passed through a macroporous adsorption resin column at a linear flow rate of 2mL / min, and the effluent is collected when the ultraviolet detection value reaches 50mAu, and the effluent is stopped when the ultraviolet detection value is lower than 100mAu; the enzymatic hydrolysate separated and purified by the macroporous adsorption resin is passed through a cation exchange resin column at a linear flow rate of 5mL / min, and the effluent is collected when the ultraviolet detection value reaches 100mAu, and the effluent is stopped when the ultraviolet detection value is lower than 200mAu.

[0114] In addition, the effluent was subjected to spray drying treatment, and the spray drying conditions were: inlet temperature 165°C, outlet temperature 70°C, to obtain wheat oligopeptides.

[0115] 2. Determination of wheat oligopeptides

[0116] 2.1.1 Chromatographic separation and component collection of wheat oligopeptides: Wheat oligopeptides were prepared into a 2 mg / mL aqueous solution, and 200 μL of the solution was taken for molecular exclusion chromatography separation. The mobile phase was a 10% acetonitrile aqueous solution (containing 0.1% formic acid) with a flow rate of 0.5 mL / min. From the 25th minute to the 50th minute, one tube was collected every minute, and the detection wavelength was 214 nm.

[0117] 2.1.2Q3 scan-high peak intensity peptide mass-to-charge ratio information analysis: Connect the Inertsil ODS-3 column to the liquid chromatograph, and take 20 μL of the separated components for injection. In the positive ion mode, the sample was scanned by Q3-Scan, and the mass-to-charge ratio scanning range was set to 100-600Da. Chromatographic conditions: mobile phase A was pure water (containing 0.1% formic acid), mobile phase B was 100% acetonitrile (containing 0.1% formic acid), and the flow rate was 0.2 mL / min. The gradient elution program was 0-15 min, B 0-40%; 15-20min, B 40-80%; 20-25 min, B 80%; 25.1-35 min, B 0%. Column oven: 40°C. Mass spectrometry conditions: ionization mode: ESI; ion spray voltage: 4.5 kV; nebulizer gas (nitrogen) flow rate: 3.0 L / min; heating gas (air) flow rate: 10 L / min; drying gas (nitrogen) flow rate: 10 L / min; desolvation tube temperature: 250°C; heating module temperature: 400°C; ion source temperature: 300°C.

[0118] 2.1.3 PIS scan-peptide secondary mass spectrometry scan: The separated components were scanned for product ions (PIS) again, and 20 μL was injected. The precursor ions were input according to the results of Q3 scan analysis, the collision energy was set to -25V and -35V, the liquid chromatography and mass spectrometry conditions were the same as Q3 scan analysis, and then the product ions generated after the collision were further analyzed.

[0119] 2.1.4 Quantitative analysis of wheat oligopeptide structure: MRM quantitative parameter optimization: The HPLC-MS / MS automatic optimization function was used to optimize the quantitative ion pairs and voltage of the standard.

[0120] Standard curve drawing: The retention time of 7 standard peptides was determined by the optimized method, and the standard peptides were mixed and diluted step by step with water to form a series of standard working solutions of 1.95, 15.625, 62.5, 125, and 250 μg / L. 5 μL was injected and the standard curve was drawn under the optimized conditions with mass concentration (X, μg / L) as the horizontal axis and peak area (Y) as the vertical axis.

[0121] Sample quantification: Dilute the wheat oligopeptide sample 100 times with pure water, centrifuge (10000 r / min for 10 min), take the supernatant, filter it with a nylon filter membrane with a pore size of 0.22 μm, and prepare the sample to be tested. The target peptide segment in wheat oligopeptide was determined by the peak area external standard method.

[0122] Liquid chromatography conditions: chromatographic column: Inertsil ODS-3 (5μm, 2.1mm*250 mm); mobile phase: A is 0.1% (v:v) formic acid in water, B is 0.1% (v:v) formic acid in acetonitrile; gradient elution program: 0-15 min, B 0-50%; 15-20 min, B 50-100%; 20-25 min, B 100%; 25.1-35 min, B 0%; flow rate: 0.2 mL / min; injection volume: 10μL; column temperature: 40℃. Mass spectrometry conditions: ionization mode: ESI, positive ion mode; ion spray voltage: +4.5 kV; nebulizer gas flow rate: nitrogen 3.0 L / min; heating gas flow rate: nitrogen 10 L / min; drying gas flow rate: nitrogen 10 L / min; DL temperature: 250°C; heating module temperature: 400°C; ion source temperature: 300°C; scan mode: multiple reaction monitoring (MRM); dwell time: 100 ms; delay time: 3 ms.

[0123] 2.2 Results and Analysis:

[0124] 2.2.1 Isolation and purification of wheat oligopeptides and component collection: The liquid chromatogram obtained by size exclusion chromatography of wheat oligopeptide samples is shown in Figure 1 As shown, the components at the absorption wavelength of 214 nm are mainly concentrated in the range of 25-50 min, so from 25 min to 50 min, one component is collected every minute for the next stage of structural analysis.

[0125] 2.2.2 Analysis of high peak intensity peptide mass-to-charge ratio information: Q3 scanning collects high peak intensity mass-to-charge ratio information to obtain peptide precursor ions: HPLC-MS / MS is used to perform precursor ion scanning on the components, and the total ion current of the main peptides in the components separated by size exclusion chromatography is analyzed. Table 1 shows the precursor ion mass-to-charge ratio corresponding to the main peptide sequence of wheat oligopeptides provided in Example 1.

[0126] Table 1

[0127]

[0128]

[0129] 2.2.3 Peptide secondary mass spectrometry scanning and peptide sequence analysis: PIS scanning fragments the high-intensity precursor ions, collects the fragment ion information of the peptides, and obtains their product ions: Perform secondary scanning on the above precursor ions to obtain the corresponding product ions, and analyze the corresponding peptide structures. Combined with the product ion information, NCBI, Uniprot and original peptide databases, the sequence structure of the peptides is determined, and finally the peptide sequences are identified from the components separated by molecular exclusion chromatography. Figure 2A is the AI ​​product ion mass spectrum of wheat oligopeptides, where: Figure 2A a in the figure is the mass spectrum obtained at -25V. Figure 2A b in the figure is the mass spectrum obtained at -45V. Figure 2B is the mass spectrum of IM product ions of wheat oligopeptides, where Figure 2B a in the figure is the mass spectrum obtained at -25V. Figure 2B b in the figure is the mass spectrum obtained at -45V. Figure 2C is the mass spectrum of AL product ions of wheat oligopeptides, where Figure 2C a in the figure is the mass spectrum obtained at -25V. Figure 2C b in FIG. 2 is the mass spectrum obtained by detection at -45 V, and Table 2 is the peptide information identified by wheat oligopeptides.

[0130] Table 2

[0131] Serial number m / z sequence Related fragment ion information 1 203.2 Ala-Leu(AL) 44-A(*);86-L(*);132-L(y1) 2 203.2 Ala-IIe(AI) 44-A(*);86-I(*) 6 263.1 IIe-Met(IM) 86-I(*);104-M(*)

[0132] 2.2.4 Quantitative analysis of wheat oligopeptide segments: The quantitative ion pair and voltage of the standard were optimized using the HPLC-MS / MS automatic optimization function. The obtained MRM optimization parameters are shown in Table 3. The peptide segments of wheat oligopeptides were quantified using the MRM optimization parameters. The quantitative chromatogram and calibration curve are shown in Figure 3A-Figure 5C ,in, Figure 3A This is the quantitative chromatogram of peptide AL standard. Figure 3B The quantitative chromatogram of wheat oligopeptides provided in Example 1 of the present invention is: Figure 3C The calibration curve of wheat oligopeptide peptide segment AL provided in Example 1 of the present invention is Y=(92101.71)X+(254241)R 2 -0.997; Figure 4A This is the quantitative chromatogram of the peptide AI standard. Figure 4B The quantitative chromatogram of wheat oligopeptides provided in Example 1 of the present invention is: Figure 4C The AI ​​calibration curve of wheat oligopeptide peptide segment provided in Example 1 of the present invention is obtained as follows: Y = (83866.1) X + (589595) R 2 -0.999; Figure 5A This is the quantitative chromatogram of the peptide IM standard. Figure 5B The quantitative chromatogram of wheat oligopeptides provided in Example 1 of the present invention is: Figure 5C The calibration curve of wheat oligopeptide peptide segment IM provided in Example 1 of the present invention is Y=(9181.82)X+(1561.87)R 2 -0.999.

[0133] Table 3

[0134]

[0135] The results showed that the contents of the target peptide segments among the wheat oligopeptides provided in Example 1 were stable. The contents of the target peptide segments in the wheat oligopeptides provided in Example 1 are shown in Table 4.

[0136] Table 4

[0137]

[0138] The content and molecular weight distribution of each component of the wheat oligopeptide product in Example 1 were detected by the national standard method, wherein the detection method of protein content was GB 5009.5, the detection method of free amino acid content was GB5009.124, the detection method of oligopeptide content was GB 5009.5 and GB 5009.124, and the detection method of molecular weight was GB / T22729. After testing, the protein content (dry basis) in the wheat oligopeptide was 98.92 g / 100 g, the free amino acid content was 3.96 g / 100 g, and the content of components with a relative molecular mass of less than 1000 Da accounted for 97%.

[0139] Comparative Example 1

[0140] 1. Preparation of wheat oligopeptides

[0141] 1) After gluten powder is mixed with water, alkaline protease and neutral protease are added in sequence for enzymolysis, and the enzymes are inactivated and the supernatant is taken for treatment after centrifugation to obtain an enzymolysis solution, wherein: the mass ratio of gluten powder to water is 1:15; the alkaline protease and neutral protease added per 100g gluten powder are 2000U and 0.8Au respectively.

[0142] 2) The enzymatic hydrolysate is sequentially subjected to centrifugal filtration treatment, macroporous adsorption resin purification treatment, and cation exchange resin purification treatment:

[0143] Among them, the rotation speed during centrifugal filtration treatment is 300rpm / min, and the filtration is carried out using a filter membrane with a pore size of 150nm. Subsequently, the enzymatic hydrolyzate after centrifugal filtration is passed through a macroporous adsorption resin column at a linear flow rate of 2mL / min, and the effluent is collected when the ultraviolet detection value reaches 50mAu, and the effluent is stopped when the ultraviolet detection value is lower than 100mAu; the enzymatic hydrolyzate after separation and purification by the macroporous adsorption resin is passed through a cation exchange resin column at a linear flow rate of 5mL / min, and the effluent is collected when the ultraviolet detection value reaches 100mAu, and the effluent is stopped when the ultraviolet detection value is lower than 200mAu.

[0144] In addition, the effluent was subjected to spray drying treatment, and the spray drying conditions were: inlet temperature 165°C, outlet temperature 70°C, to obtain wheat oligopeptides.

[0145] The wheat oligopeptides were detected by the detection method provided in Example 1, and the test results showed that the wheat oligopeptides included 0.25% AL, 0.61% AI, and 0.01% IM.

[0146] Test Case

[0147] 1.1 Cell experimental methods

[0148] Sterile water was used as a control group and the wheat oligopeptide provided in Example 1 was used as an experimental group, wherein the experimental groups included concentrations of 0.5 mg / mL, 1 mg / mL, 5 mg / mL, and 10 mg / mL, respectively, with 3 replicates in each group.

[0149] After the frozen C2C12 was revived, it was subcultured in a basal medium containing 10% inactivated bovine serum, 100 IU / mL penicillin, and 100 IU / mL streptomycin at 37°C and 5% CO2 saturated humidity. The cells used in the experiment were in the logarithmic growth phase. Take the normally cultured myoblast C2C12, remove the original culture medium, add PBS to wash, add trypsin to stop digestion, gently blow the bottle wall with a pipette, and take 15 μL of cell suspension for counting. The remaining cell suspension was centrifuged at 1000 rpm for 5 minutes, resuspended with culture medium, and plated in a 24-well plate at 4×10 4 Each group was plated with 3 replicates and cultured overnight at 37°C and 5% CO2 saturated humidity. Myoblast C2C12 cells were then placed in the solution of the control group and the test group, and relevant tests were performed after 24 hours of treatment.

[0150] The cell proliferation assay was performed using the CCK-8 kit: C2C12 cells were cultured at 4 × 10 4Cells were inoculated into 24-well culture plates, and the control group and experimental group were treated separately. The wells without cells were used as blank controls. After culturing for 24 hours at 37°C and 5% CO2, 10 μL of CCK-8 solution was added and cultured for another 3 hours at 37°C. The optical density of the cells was then measured with an ELISA reader, with an absorbance of 450nm, and the proliferation test results were recorded. The cell proliferation rate was calculated as follows:

[0151] Growth rate = (experimental OD value - blank OD value) / (control OD value - blank OD value) × 100%

[0152] Collect cells, centrifuge at 1000rpm for 5min, discard the supernatant, wash with PBS, centrifuge at 1000rpm for 5min, discard the supernatant, add buffer (4×) to dilute to (1×). Take 100μL of dilution and resuspend, add 5μL Annevix V-AlexaFluor 647, place at room temperature in the dark for 5min, then add 10μL PI, place at room temperature in the dark for 5min, add 150μL (1×) buffer, and detect on flow cytometer. Use apoptosis detection kit for cell apoptosis experiment. Myoblast C2C12 cells were inoculated in 12 culture dishes, cultured for 24h, and treated with drugs for 24h. Cells treated with equal amount of PBS were used as control, and 5μL Annexin V and 10μL 20μg / mL PI reagent were added to treated cells and control cells, respectively. Cells were incubated in the dark at room temperature for 10-15min, and the level of cell apoptosis was detected by flow cytometry.

[0153] 1.2 RNA extraction and sequencing

[0154] RNA-seq detection was performed by Wuhan Ruixing Biotechnology Co., Ltd. 1 μg of total RNA was treated with RQ1 DNase (M6101, Promega, USA) for each sample to remove DNA, and then used Universal V8 RNA-seq library Prep Kit For Illumina (NR605, Vazyme, China) was used for directional RNA-seq library preparation. mRNA was captured by VAHTS mRNA capture beads (N401, Vazyme, China), fragmented RNA was converted into double-stranded cDNA, and after end repair and A-tailing, the DNA was ligated to VAHTS RNA Multiplex Oligos Set 1 for Illumina (N323, Vazyme, China). The ligation products were amplified, purified, quantified, and stored at -80°C before sequencing. The strand labeled with dUTP (the second cDNA strand) was not amplified, allowing specific sequencing. For high-throughput sequencing, libraries were prepared according to the manufacturer's instructions and applied to the Illumina Novaseq 6 000 system for 150 nt paired-end sequencing.

[0155] 1.3 Differentially expressed genes (DEG) analysis

[0156] The R Bioconductor software package DESeq2 (Love, Huber et al. 2014) was used to screen differentially expressed genes (DEGs). The screening conditions were P < 0.05, fold change > 1.5 or < 0.67.

[0157] 1.3.1 Functional enrichment analysis

[0158] DEGs were functionally classified, GO and KEGG pathways were identified using the KOBAS2.0 server, and the hypergeometric test and Benjamini-Hochberg FDR control procedure were used to determine the enrichment degree of each item.

[0159] 1.3.2 PPI Network Construction

[0160] Gene sequences were mapped to PPI data using the Search Tool for Retrieval of Interacting Genes (STRING) database to construct PPI networks. The symbols of DEGs were imported into the database and high-resolution bitmaps were generated. The bitmaps only included interactors with a composite confidence score of 0.7 or higher. Hotspot modules were obtained in large PPI networks using the Cytoscape plugin Molecular Complex Detection (MCODE). In this study, the MCODE parameters were: cutoff degree = 2; cluster discovery, barber; node score cutoff = 0.2; K-core = 2; maximum depth = 100 (Bader & Hogue, 2003). GO enrichment analysis was performed using DAVID to analyze genes in the modules. The connectivity of the PPI network was calculated using the Cytoscape 3.9.1 plugin CytoHubba, and the top 10 genes in the PPI network were identified. The PPI network, modules, and node degrees of the top 10 genes were visualized using Cytoscape software.

[0161] 1.4 qRT-PCR verification of key response genes

[0162] cDNA was synthesized on a thermocycle instrument using a reverse transcription kit, and the reverse transcription conditions were 42°C for 5 min, 37°C for 15 min, and 85°C for 5 s. qPCR was then performed on an ABIQuantStudio 5 instrument, with the program set to 95°C pre-denaturation for 10 min, 95°C denaturation for 15 s, 60°C annealing and extension for 1 min, and 40 cycles of denaturation and extension. Three technical replicates were performed for each sample. The relative expression of each transcript mRNA was then calculated, normalized with GAPDH as an internal reference gene, and analyzed using the 2-ΔΔCT method (Livak and Schmittgen 2001). Two-way ANOVA or t-test statistical analysis was performed using GraphPad Prism software (version 8.0, San Diego, CA).

[0163] RT-qPCR was used to verify alternative splicing events (ASEs). Primer design principle: one primer is designed at the trans-exon position of the constitutive exon and the variable exon of the transcript, and the other primer is designed at the constitutive exon of the transcript; if the trans-exon primer is designed on the template transcript, it is to detect the splicing of the template transcript; if it is designed on the alternative splicing transcript, it is to detect the splicing of the alternative transcript. The ratio of the two is calculated as the proportion of the alternative splicing event of the sample, and the alternative splicing differences between different samples are compared. The primers used for quantitative (q)PCR analysis are shown in Table 5.

[0164] Table 5

[0165]

[0166] 2 Research results

[0167] 2.1 Wheat oligopeptides inhibit C2C12 apoptosis

[0168] The results showed that the experimental group treated C2C12 cells with different concentrations (0.5, 1, 5, 10, unit mg / ml) of wheat oligopeptides for 24 hours. Compared with the control group, 10mg / ml wheat oligopeptides treated for 24 hours had an inhibitory effect on cell proliferation, and the T test was significant; 5mg / ml wheat oligopeptides treated for 24 hours inhibited cell apoptosis, and the T test was significant; 0.5mg / ml, 1mg / ml and 10mg / ml wheat oligopeptides treated for 24 hours had a tendency to inhibit cell apoptosis, and the T test was significant. Fig. 6A and Figure 6B As shown, Fig. 6A Effects of wheat oligopeptides on cell proliferation, Figure 6B Effect of wheat oligopeptides on cell apoptosis. From the above experiments, we can see that 5mg / ml wheat oligopeptides promote the proliferation of myoblasts C2C12 cells and inhibit the apoptosis of myoblasts C2C12 cells, and 10mg / ml wheat oligopeptides have an inhibitory effect on the proliferation of myoblasts C2C12 cells. 5mg / ml wheat oligopeptides are determined to be the optimal concentration for inhibiting C2C12 cell apoptosis, and the next experiment is carried out.

[0169] 2.2 Functional analysis of DEGs after wheat oligopeptide treatment of C2C12

[0170] By RNA-seq, 370 differentially expressed genes were identified, of which 109 genes were upregulated and 261 genes were downregulated. Fig. 7A It is a PCA diagram based on the FPKM values ​​of all genes measured, and the circle of each group is the confidence circle; Figure 7B To display all differentially expressed genes (DEGS) between treatment and control samples using DEseq2, P < 0.05 and FC ≥ 1.5 or ≤ 0.67; Figure 7C The FPKM hierarchical clustering heat map of all DEGs. The experimental results showed that the number of down-regulated genes was significantly more than that of up-regulated genes, indicating that 5 mg / ml wheat oligopeptide treatment of C2C12 cells has the function of inhibiting gene expression.

[0171] The GO analysis results of the above gene expression showed that the top 10 pathways enriched by up-regulated genes were neutrophil chemotaxis, response to lipopolysaccharide, inflammatory response, glutathione metabolism, chemokine-mediated signaling pathways, immune response, response to bacteria, xenobiotic metabolism, positive regulation of ERK1 and ERK2 cascades, and positive regulation of peptide tyrosine phosphorylation; the top 10 pathways enriched by down-regulated genes were redox process, lipid metabolism, transmembrane transport, ion transport, sodium ion transmembrane transport, kidney development, steroid metabolism, fatty acid metabolism, sodium ion transport, and proteolysis. These results emphasize the important role of wheat oligopeptides in myoblast proliferation and apoptosis. Fig.7D The most enriched GO analysis results for upregulated DEGs; Fig. 7E The most enriched GO analysis results for down-regulated DEGs.

[0172] The KEGG analysis results of the above gene expression showed that the top 10 enriched pathways of up-regulated genes were TNF signaling pathway, IL-17 signaling pathway, metabolism of cytochrome P450 on exogenous drugs, rheumatoid arthritis, fluid shear stress and atherosclerosis, complement and coagulation cascade, chemical carcinogenesis, interaction between viral proteins and cytokines and cytokine receptors, glutathione metabolism, and drug metabolism-cytochrome P450; the top 10 enriched pathways of down-regulated genes were metabolic pathways, arachidonic acid metabolism, PPAR signaling pathway, glycine, serine and acid metabolism, peroxisome, carbohydrate digestion and absorption, retinol metabolism, fatty acid degradation, phenylalanine metabolism, and terpenoid skeleton biosynthesis. Fig. 8A The top 10 pathways enriched for up-regulated genes were Figure 8B The top 10 pathways enriched for down-regulated genes.

[0173] 2.3 Protein–protein interaction (PPI) network construction

[0174] The PPI network of differentially expressed genes (DEGs) was constructed by analyzing the online database STRING (https: / / www.string-db.org / ). The PPI interaction parameter interaction score ≥ 0.7 was used to screen hub genes using the cytoscape plug-in Molecular Complex Detection (MCODE). The top 10 were identified based on the scores, and the interaction network of these 10 genes was reconstructed. Among them, Cxcl1, Ccl5, Ccl2, and Cxcl5 belong to genes in the chemokine pathway, Il-6 belongs to genes related to the immune inflammation pathway, Cyp2e1 and Gpx3 belong to genes related to the redox process pathway, Mmp3 belongs to genes related to the TNF signaling pathway, Gsta2 belongs to genes related to the glutathione metabolic process pathway, and Cxcr4 belongs to genes related to the signal transduction pathway. The results are as follows Fig. 9 As shown, the circle represents the hub gene, red indicates up-regulated gene expression, and blue indicates down-regulated gene expression.

[0175] Functional annotation of hub genes obtained by the above method showed that hub genes tended to be enriched in "chemokine-mediated signaling pathway", "cell response to chemokines" and "chemokine response" as biological processes. Fig. 10A , Fig. 10B As shown, Fig. 10A This is an ontology function annotation diagram, and the red font nodes represent hub genes. Fig. 10B Figure 2 shows the FPKM and statistical difference of important Hub genes. Error bars represent mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001.

[0176] 2.4 qRT-PCR verification of key response genes

[0177] Quantitative real-time fluorescence PCR (qRT-PCR) was used to analyze the expression levels of five DEGs, including several hub genes: upregulated (Ccl2, Ccl5, Cxcl1, Cxcl5) and downregulated (Cxcr4), to verify the expression of key sequence data of the transcriptome.

[0178] RT-qPCR was used to verify alternative splicing events (ASEs). Primer design principles: one primer is designed at the trans-exon position of the constitutive exon and the variable exon of the transcript, and the other primer is designed at the constitutive exon of the transcript; if the trans-exon primer is designed on the template transcript, it is to detect the splicing of the template transcript; if it is designed on the alternative splicing transcript, it is to detect the splicing of the alternative transcript. The ratio of the two is calculated as the proportion of the alternative splicing event of the sample, and the alternative splicing differences between different samples are compared.

[0179] The DEG analysis of the experimental results showed that the qRT-PCR results were consistent with the RNA-Seq data, with a validation pass rate of 100%. Fig.11 As shown: Compared with the control group, the expression of Cxcr4 gene in the experimental group was reduced, and the two-way ANOVA showed significant differences, which was consistent with expectations; compared with the control group, the expression of Cxcl5, Cxcl1, Ccl2, and Ccl5 genes in the experimental group was increased, and the two-way ANOVA showed significant differences, which was consistent with expectations. Fig.11 .

[0180] The present invention identified the common DEGs that wheat oligopeptides affect the proliferation and apoptosis of myoblasts C2C12, and enriched them. The comprehensive GO and KEGG analysis showed that wheat oligopeptides are widely involved in regulating muscle growth and development, among which inflammatory response, chemokine-mediated signaling pathway, immune response pathway, TNF signaling pathway, IL-17 signaling pathway, and redox process pathway are closely related to myoblast proliferation and differentiation, which deserves our attention. The results of the PPI network analysis of the present invention showed that the chemokine CXCL1, CCL2, and CCL5 genes were related to myoblasts, and further confirmed that chemokine response dominated the proliferation / apoptosis of C2C12 cells treated with wheat oligopeptides. In summary, this study provides ideas for further exploring the molecular mechanism of the biological function of wheat oligopeptides and the use of wheat oligopeptides to intervene in sarcopenia. The physiological mechanism of wheat oligopeptides in promoting muscle regeneration needs to be deeply analyzed and discussed in more related experiments. Wheat oligopeptides are expected to become a green and effective physiological regulator for the treatment of sarcopenia.

[0181] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein with equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.

Claims

1. A wheat oligopeptide, characterized in that: The wheat oligopeptide composition at least includes peptide segments Ala-Leu, Ala-IIe and IIe-Met; The mass content of Ala-Leu is 0.2%-0.4%, the mass content of Ala-IIe is 0.5%-0.7%, and the mass content of IIe-Met is 0.02%-0.05%.

2. The wheat oligopeptide according to claim 1, characterized in that The mass content of the Ala-Leu is 0.2%-0.3%, the mass content of the Ala-IIe is 0.6%-0.7%, and the mass content of the IIe-Met is 0.02%-0.04%.

3. The wheat oligopeptide according to claim 1 or 2, characterized in that The wheat oligopeptide has a protein content of 95%-99%, a free amino acid content of 2%-5%, and a component content of less than 1000Da relative molecular weight of 92%-94%.

4. A method for preparing the wheat oligopeptide according to any one of claims 1 to 3, characterized in that: The following steps are involved: 1) using trypsin and neutral protease to enzymatically hydrolyze the gluten solution in sequence to obtain a first enzymatic hydrolyzate; 2) performing centrifugation and preliminary separation treatment on the first enzymatic hydrolysate in sequence to obtain a second enzymatic hydrolysate with a molecular weight of 200-1000Da; 3) The second enzymatic hydrolyzate is sequentially subjected to filtration treatment, macroporous adsorption resin purification treatment, and cation exchange resin purification treatment to obtain wheat oligopeptides.

5. The preparation method according to claim 4, characterized in that: In step 1), the mass ratio of gluten to water in the gluten solution is 1:(10-20); The trypsin added to every 100g of the gluten powder is 2000U; The neutral protease added to each 100g of the gluten powder is 0.8Au.

6. The preparation method according to claim 4 or 5, characterized in that: In step 2), the centrifugation-preliminary separation process comprises the following steps: The first enzymatic hydrolysate is centrifuged to separate the supernatant, and then the supernatant is separated using a 1000Da membrane to obtain a filtrate including the target product; The filtrate is separated using a 200Da membrane to obtain the second enzymatic hydrolyzate with a molecular weight of 200-1000Da.

7. The preparation method according to any one of claims 4 to 6, characterized in that: The rotation speed in the centrifugal filtration process is 200-400 rpm / min, and the pore size of the filter membrane is 120-160 nm.

8. The preparation method according to any one of claims 4 to 7, characterized in that: The macroporous adsorption resin purification process comprises the following steps: The enzymatic hydrolysate after centrifugal filtration is passed through a macroporous adsorption resin column at a linear flow rate of 1-5 mL / min, and the effluent is collected when the ultraviolet detection value reaches 50 mAu, and the effluent is stopped when the ultraviolet detection value is lower than 100 mAu; And / or, the cation exchange resin purification process comprises the following steps: The enzymatic hydrolyzate separated and purified by the macroporous adsorption resin is passed through a cation exchange resin column at a linear flow rate of 1-10 mL / min, and the effluent is collected when the ultraviolet detection value reaches 100 mAu, and the effluent is stopped when the ultraviolet detection value is lower than 200 mAu.

9. The preparation method according to any one of claims 4 to 8, characterized in that: The method also includes spray drying the wheat oligopeptide, wherein the inlet temperature of the spray drying is 160-170°C and the outlet temperature is 60-80°C.

10. Use of the wheat oligopeptide according to any one of claims 1 to 3 in a product for inhibiting apoptosis of myoblast C2C12 cells and / or promoting proliferation of myoblast C2C12 cells.